Vivos (RDGL) Other Non-Current Liabilities (2013 - 2024)

Vivos (RDGL) posted Other Non-Current Liabilities of $40949.0 for Q4 2024, up 309.49% sequentially from $10000.0 in Q3 2023.

Vivos (RDGL) Other Non-Current Liabilities (2013 - 2024) Analysis & Trends

Vivos has reported Other Non-Current Liabilities for 7 years, with the latest figure at $40949.0 in Q4 2024.

Quarterly Other Non-Current Liabilities changed N/A year-over-year to $40949.0 in Q4 2024, while the trailing twelve-month figure through Dec 2024 was $40949.0 (changed N/A YoY) and the FY2024 annual result came in at $40949.0, changed N/A from the prior year.
Other Non-Current Liabilities improved to $40949.0 in Q4 2024 per RDGL's latest filing, from $10000.0 in the prior quarter.
Over five years, Other Non-Current Liabilities peaked at $40949.0 in Q4 2024 and troughed at $10000.0 in Q3 2023.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Abbott Laboratories	202.72 Bn	197.12 Bn	7.27 Bn
2	Stryker	126.42 Bn	122.94 Bn	4.50 Bn
3	Medtronic	119.75 Bn	110.53 Bn	6.41 Bn
4	Boston Scientific	74.13 Bn	73.60 Bn	3.85 Bn
5	Edwards Lifesciences	51.78 Bn	47.53 Bn	1.35 Bn
6	Dexcom	35.29 Bn	33.34 Bn	830.00 Mn
7	GE HealthCare Technologies	33.95 Bn	31.85 Bn	2.18 Bn
8	Koninklijke Philips	26.22 Bn	22.90 Bn	4.55 Bn
9	Steris	23.21 Bn	22.73 Bn	684.20 Mn
10	Vivos	22.64 Mn	21.08 Mn	-3,105.00

Download Data